BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 26721202)

  • 1. Downregulation of Nrf2 by the combination of TRAIL and Valproic acid induces apoptotic cell death of TRAIL-resistant papillary thyroid cancer cells via suppression of Bcl-xL.
    Cha HY; Lee BS; Chang JW; Park JK; Han JH; Kim YS; Shin YS; Byeon HK; Kim CH
    Cancer Lett; 2016 Mar; 372(1):65-74. PubMed ID: 26721202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells.
    Sung ES; Kim A; Park JS; Chung J; Kwon MH; Kim YS
    Apoptosis; 2010 Oct; 15(10):1256-69. PubMed ID: 20582477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response.
    Lagneaux L; Gillet N; Stamatopoulos B; Delforge A; Dejeneffe M; Massy M; Meuleman N; Kentos A; Martiat P; Willems L; Bron D
    Exp Hematol; 2007 Oct; 35(10):1527-37. PubMed ID: 17697742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. R-roscovitine sensitizes anaplastic thyroid carcinoma cells to TRAIL-induced apoptosis via regulation of IKK/NF-kappaB pathway.
    Festa M; Petrella A; Alfano S; Parente L
    Int J Cancer; 2009 Jun; 124(11):2728-36. PubMed ID: 19230027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
    Ray S; Almasan A
    Cancer Res; 2003 Aug; 63(15):4713-23. PubMed ID: 12907654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Overcoming acquired resistance to tumor necrosis factor-related apoptosis-inducing ligand by Bcl-XL small interfering RNA in human colon cancer].
    Zhu HB; Huang XF; Hu JZ; Zhou W; Chen W; Chen LL; He C
    Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):245-9. PubMed ID: 18788624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valproic acid sensitizes K562 erythroleukemia cells to TRAIL/Apo2L-induced apoptosis.
    Iacomino G; Medici MC; Russo GL
    Anticancer Res; 2008; 28(2A):855-64. PubMed ID: 18507029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galiximab signals B-NHL cells and inhibits the activities of NF-κB-induced YY1- and snail-resistant factors: mechanism of sensitization to apoptosis by chemoimmunotherapeutic drugs.
    Martinez-Paniagua MA; Vega MI; Huerta-Yepez S; Baritaki S; Vega GG; Hariharan K; Bonavida B
    Mol Cancer Ther; 2012 Mar; 11(3):572-81. PubMed ID: 22267549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro.
    Bai J; Sui J; Demirjian A; Vollmer CM; Marasco W; Callery MP
    Cancer Res; 2005 Mar; 65(6):2344-52. PubMed ID: 15781649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxaliplatin sensitizes human colon cancer cells to TRAIL through JNK-dependent phosphorylation of Bcl-xL.
    El Fajoui Z; Toscano F; Jacquemin G; Abello J; Scoazec JY; Micheau O; Saurin JC
    Gastroenterology; 2011 Aug; 141(2):663-73. PubMed ID: 21683075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
    Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
    Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dexamethasone inhibits TRAIL-induced apoptosis of thyroid cancer cells via Bcl-xL induction.
    Petrella A; Ercolino SF; Festa M; Gentilella A; Tosco A; Conzen SD; Parente L
    Eur J Cancer; 2006 Dec; 42(18):3287-93. PubMed ID: 17070682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy on anaplastic thyroid carcinoma of valproic acid alone or in combination with doxorubicin, a synthetic chenodeoxycholic acid derivative, or lactacystin.
    Kim TH; Yoo YH; Kang DY; Suh H; Park MK; Park KJ; Kim SH
    Int J Oncol; 2009 May; 34(5):1353-62. PubMed ID: 19360347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.
    Mitsiades N; Poulaki V; Tseleni-Balafouta S; Koutras DA; Stamenkovic I
    Cancer Res; 2000 Aug; 60(15):4122-9. PubMed ID: 10945619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Experimental study on the mechanism of the apoptosis of leukemic cells induced by valproic acid].
    Xue HM; Li WY; Guo HX; Xia Y; Chen Q; Liu Y
    Zhonghua Er Ke Za Zhi; 2005 Dec; 43(12):894-8. PubMed ID: 16412349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRAIL-induced apoptosis of thyroid cancer cells: potential for therapeutic intervention.
    Ahmad M; Shi Y
    Oncogene; 2000 Jul; 19(30):3363-71. PubMed ID: 10918593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitization of mesothelioma to TRAIL apoptosis by inhibition of histone deacetylase: role of Bcl-xL down-regulation.
    Neuzil J; Swettenham E; Gellert N
    Biochem Biophys Res Commun; 2004 Jan; 314(1):186-91. PubMed ID: 14715264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression.
    Huerta-Yepez S; Vega M; Jazirehi A; Garban H; Hongo F; Cheng G; Bonavida B
    Oncogene; 2004 Jun; 23(29):4993-5003. PubMed ID: 15048072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combinatorial action of the HDAC inhibitor trichostatin A and etoposide induces caspase-mediated AIF-dependent apoptotic cell death in non-small cell lung carcinoma cells.
    Hajji N; Wallenborg K; Vlachos P; Nyman U; Hermanson O; Joseph B
    Oncogene; 2008 May; 27(22):3134-44. PubMed ID: 18071312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.
    Chen KF; Chen HL; Liu CY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
    Biochem Pharmacol; 2012 Mar; 83(6):769-77. PubMed ID: 22230479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.